期刊文献+

肾癌患者围术期血清TGF-β_1、TNF-α及IL-2水平变化研究 被引量:2

下载PDF
导出
摘要 目的探讨肾癌患者血清TGF-β_1、TNF-α及IL-2水平的变化规律。方法选取2006年9月~2010年1月于笔者所在医院进行手术治疗的36例肾癌患者为研究对象,分别于术前、术后即刻及术后24 h的血清TGF-β_1、TNF-α及IL-2水平进行检测,后将结果加以研究及比较。结果经研究比较发现,术前血清IL-2水平明显高于术后即刻,P<0.05,而术后24 h血清IL-2水平较术后即刻有所升高,P<0.05,有显著性差异。血清TGF-β_1、TNF-α呈下降趋势,术前明显高于术后即刻及术后24 h,P<0.05或P<0.01。结论肾癌患者围术期血清TGF-β_1、TNF-α及IL-2水平变化较大,可进一步研究探讨,以为其治疗提供依据。
作者 史斌
出处 《中国医学创新》 CAS 2010年第16期68-69,共2页 Medical Innovation of China
  • 相关文献

参考文献4

  • 1刘广华,李汉忠,夏溟,纪志刚,谢毅.多中心肾癌发生机制探讨[J].临床泌尿外科杂志,2006,21(8):579-581. 被引量:8
  • 2Adisak W,Sakdipat S,Suradej H,et al.Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells.J Orthopaedic Res,2005,23(6):1460-1466.
  • 3Martinez LA,Naguibneva I,Lehrmann H,et al.Synthetic small inhibiting RNAs:Efficienct tools to inactivate oncogenic mutations and restore p53 pathways.PNAS,2002,99(23):14849-14854.
  • 4Eisen T,Bukowski RM,Staehler M,et al.Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC):Impact of crossover on survival.J Clin Oncol,2006,24:4524.

二级参考文献9

  • 1Junker K, Schlichter A, Junker U, et al. cytogenetic,histopathologic, and immunologic studies of multifocalrenal cell carcinoma[J]. Cancer, 1997, 79 (5):975 -981.
  • 2Tokuda N, Natio S. incidental renal cell carcinoma[J].Japanese J Urol,1999,12:561-566.
  • 3Cheng W S, Farrow G W, Zincke H. the incidence of multicentricily in renal cell carcinoma[J]. J Urol, 1991,146(5): 1221 - 1223.
  • 4Klescher B A, Qian J, Bostwick D, et al. prospective analysis of mutifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume, and deoxyribonucleic acid ploidy[J]. J Urol,1995,153(3):904- 906.
  • 5Matthew W, Kathleen O, Ronda B, et al. the incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomyFJ~. J Urol,1995,154:968-971.
  • 6Junker K, Schlichter A, Hinderman W, et al. genetic characterization of multifocal tumor growth in renal cell carcinoma[J]. Kidney Int,1999,56(4) :1291-1294.
  • 7Srivastava A, Laidler P, Hughes L E, et al. the prognostic significance of tumor vascularity in intermediatethickness(0.76- 4.00mm thick) skin melanoma: a quantitative histologic study[J]. Am J Pathol, 1988,133(2) :419-23.
  • 8Yoshino S, Kato M. prognostic significance of microvessel count in low stage renal cell carcinoma[J].Int J Urol,1995,2(a) :156-60.
  • 9李泉林,关宏伟,张秋萍,薛军,王法鹏,高鹤立,韩辉,张仁科.肾癌多中心病灶发生机理的探讨[J].中华泌尿外科杂志,2003,24(4):232-234. 被引量:29

共引文献7

同被引文献20

  • 1刘颖,凌世淦,于继云.肾癌相关基因的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):110-112. 被引量:6
  • 2Jemal A,Siegel R,Ward E,et al.Cancer statistics[J].CA Cancer J Clin,2006,56:106-130.
  • 3Ghosh PM.What controls pten and what it controls(in prostate cancer)[J].Asian J Androl,2011.
  • 4Haas-Kogan D,Stokoe D.Pten in brain tumors[J].Expert RevNeurother,2008,8(4):599-610.
  • 5Han KS,Jeong IG,Joung JY,et al.Clinical value of pten in patients withsuperficial bladder cancer[J].Urol Int,2008,80(3):264-269.
  • 6Feliciano P.Pten cernas in melanoma[J].Nat Genet,2011,43(12):1178.
  • 7Krausch M,Raffel A,Anlauf M,et al.Loss of pten expression inneuroendocrine pancreatic tumors[J].Horm Metab Res,2011,43(12):865-871.
  • 8Mallis A,Teymoortash A,Mastronikolis NS,et al.Mmp-2expression in102 patients with glottic laryngeal cancer[J].Eur ArchOtorhinolaryngol,2012,269(2):639-642.
  • 9Noh S,Jung JJ,Jung M,et al.Mmp-2as a putative biomarker forcarcinomatosis in gastric cancer[J].Hepatogastroenterology,2011,58(112):2015-2019.
  • 10JEMAL A,SIEGEL R, WARD E, et al. Cancer statistics, 2006 [ J ]. CA : A Cancer JourTml for Clinicians,2006,56(2) : 106-130.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部